ES2173641T3 - Composicion de derivados opiaceos para la fabricacion de medicamentos. - Google Patents

Composicion de derivados opiaceos para la fabricacion de medicamentos.

Info

Publication number
ES2173641T3
ES2173641T3 ES98956656T ES98956656T ES2173641T3 ES 2173641 T3 ES2173641 T3 ES 2173641T3 ES 98956656 T ES98956656 T ES 98956656T ES 98956656 T ES98956656 T ES 98956656T ES 2173641 T3 ES2173641 T3 ES 2173641T3
Authority
ES
Spain
Prior art keywords
patient
antinociceptive
conjugate
vivo
introducing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98956656T
Other languages
English (en)
Inventor
Alan M Ezrin
Dominique P Bridon
Darren L Holmes
Peter Milner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ConjuChem Inc
Original Assignee
ConjuChem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ConjuChem Inc filed Critical ConjuChem Inc
Application granted granted Critical
Publication of ES2173641T3 publication Critical patent/ES2173641T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Utilización de una composición para la fabricación de un medicamento, constando dicha composición de un derivado de un opiáceo y análogos del mismo, caracterizada porque el derivado contiene un grupo funcional reactivo, que reacciona con grupos amino, grupos hidroxilo o grupos tiol de componentes de la sangre para formar enlaces covalentes estables, seleccionándose dicho grupo funcional reactivo entre N-hidroxi-succinimida, N-hidroxi-sulfo-succinimida y un grupo de maleimida, para aliviar el dolor o proporcionar un efecto analgésico.
ES98956656T 1997-11-07 1998-11-06 Composicion de derivados opiaceos para la fabricacion de medicamentos. Expired - Lifetime ES2173641T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6470597P 1997-11-07 1997-11-07

Publications (1)

Publication Number Publication Date
ES2173641T3 true ES2173641T3 (es) 2002-10-16

Family

ID=22057753

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98956656T Expired - Lifetime ES2173641T3 (es) 1997-11-07 1998-11-06 Composicion de derivados opiaceos para la fabricacion de medicamentos.

Country Status (9)

Country Link
EP (2) EP1028971A2 (es)
JP (2) JP2001522863A (es)
AT (2) ATE235513T1 (es)
AU (3) AU750387B2 (es)
CA (2) CA2309205A1 (es)
DE (2) DE69812727D1 (es)
ES (1) ES2173641T3 (es)
IL (1) IL135835A0 (es)
WO (3) WO1999024074A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6437092B1 (en) 1998-11-06 2002-08-20 Conjuchem, Inc. Conjugates of opioids and endogenous carriers
JP2002512640A (ja) * 1998-03-23 2002-04-23 コンジュケム，インコーポレーテッド 持続性治療薬の局所送達
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
MEP42108A (en) 1998-10-23 2011-02-10 Kiren Amgen Inc Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
EP2110381A1 (en) 1999-05-17 2009-10-21 ConjuChem Biotechnologies Inc. Long lasting fusion peptide inhibitors of viral infection
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
CA2623458A1 (en) * 1999-05-17 2000-11-23 Conjuchem Biotechnologies Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US7144854B1 (en) 1999-09-10 2006-12-05 Conjuchem, Inc. Long lasting anti-angiogenic peptides
CN101289500A (zh) * 1999-05-17 2008-10-22 康久化学生物技术公司 病毒感染的长效融合肽抑制剂
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6329336B1 (en) * 1999-05-17 2001-12-11 Conjuchem, Inc. Long lasting insulinotropic peptides
US6706892B1 (en) 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
US7090851B1 (en) 1999-09-10 2006-08-15 Conjuchem Inc. Long lasting fusion peptide inhibitors of viral infection
US7268113B2 (en) 2001-02-02 2007-09-11 Conjuchem Biotechnologies Inc. Long lasting growth hormone releasing factor derivatives
EA006160B1 (ru) 2001-02-16 2005-10-27 Конджачем, Инк. Долгоживущий глюкагоноподобный пептид 2(glp-2, гпп-2) для лечения желудочно-кишечных заболеваний и расстройств
PT1479691E (pt) 2001-05-31 2007-02-28 John Erickson Inibidores de péptido de fusão de longa duração para a infecção por hiv
ATE466953T1 (de) 2003-01-17 2010-05-15 Advanced Proteome Therapeutics Verfahren zur identifizierung aktivierter polymer-komplexe zur sekundären stellen-spezifischen modifikation von protein ziel-gruppen.
PL1745078T3 (pl) * 2004-04-23 2009-12-31 Conjuchem Biotechnologies Inc Sposób oczyszczania koniugatów albumin
EP1773400A2 (en) 2004-07-08 2007-04-18 Amgen Inc. Therapeutic peptides
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
WO2008047241A2 (en) 2006-10-16 2008-04-24 Conjuchem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
GB201204868D0 (en) 2012-03-20 2012-05-02 San Raffaele Centro Fond Peptides
CN107074716A (zh) * 2014-07-18 2017-08-18 比奥考金特有限责任公司 包含水杨酸酯和聚水杨酸酯的组合物及方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59138958A (ja) * 1983-01-31 1984-08-09 Mitsubishi Chem Ind Ltd 抗血清
US4784955A (en) * 1984-09-21 1988-11-15 Miles Inc. Immunogen conjugates and the use thereof in a dihydropyridine assay
IE901736L (en) * 1989-05-17 1990-11-17 Fuller H B Licensing Financ Polypeptide-antibody conjugate for inhibiting cell adhesion
DK608589D0 (da) * 1989-12-01 1989-12-01 Holm Arne Kemisk fremgangsmaade
US5292362A (en) * 1990-07-27 1994-03-08 The Trustees Of Columbia University In The City Of New York Tissue bonding and sealing composition and method of using the same
JPH04364200A (ja) * 1991-06-10 1992-12-16 Unitika Ltd 細胞接着性アルブミン
US5399671A (en) * 1992-11-18 1995-03-21 Kluger; Ronald Specifically crosslinked hemoglobin with free functionality
US5840733A (en) * 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes

Also Published As

Publication number Publication date
EP1028971A2 (en) 2000-08-23
EP1007561A2 (en) 2000-06-14
JP2001522817A (ja) 2001-11-20
DE69812727D1 (de) 2003-04-30
ATE235513T1 (de) 2003-04-15
WO1999024074A2 (en) 1999-05-20
AU1312799A (en) 1999-05-31
IL135835A0 (en) 2001-05-20
AU1385699A (en) 1999-05-31
WO1999024076A9 (en) 2000-06-08
DE69804974T2 (de) 2002-11-07
CA2301799A1 (en) 1999-05-20
WO1999024462A3 (en) 1999-08-26
JP2001522863A (ja) 2001-11-20
CA2309205A1 (en) 1999-05-20
DE69804974D1 (de) 2002-05-23
WO1999024076A2 (en) 1999-05-20
ATE216402T1 (de) 2002-05-15
AU1519799A (en) 1999-05-31
WO1999024074A3 (en) 1999-08-19
WO1999024462A2 (en) 1999-05-20
WO1999024076A3 (en) 1999-08-19
EP1007561B1 (en) 2002-04-17
CA2301799C (en) 2007-08-07
AU750387B2 (en) 2002-07-18

Similar Documents

Publication Publication Date Title
ES2173641T3 (es) Composicion de derivados opiaceos para la fabricacion de medicamentos.
US20070082041A1 (en) Topical delivery of codrugs
ATE235895T1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
HU912442D0 (en) Process for the production of medical preparations with continuous active agent release
NO20015584L (no) Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling
PT740650E (pt) Co-farmacos como um metodo de administracao controlada de farmacos
NL8403618A (nl) Werkwijze voor het percutaan toedienen van metoclopramide.
BRPI0416028A (pt) composto, conjugados do composto e de anticorpo-medicamento, composições farmacêuticas, usos dos conjugados, métodos para tratamento de cáncer, de uma doença auto-imune, de uma doença infecciosa e de um paciente, método para inibir a proliferação ou matar as células de tumor ou células cancerìgenas, método de inibição do crescimento de células de tumor, análise para detectar células de cáncer e artigo de manufatura
BR0016339A (pt) Composição de lcrf, conjugado de lcrf, composição de peptìdeo, complexo de lcrf conjugado a ligando múltiplo, complexo de polissorbato, complexo de lcrf conjugado, aquosamente solúvel estável, forma de dosagem de administração oral para o tratamento da obesidade, métodos de tratamento da obesidade em um paciente mamìfero humano ou não humano, de tratamento modo profilático ou intervencional da obesidade potencial ou desenvolvida em um paciente mamìfero humano ou não humano e de prolongamento da atividade de lcrf em um sistema in vivo ou in vitro, e, composto
WO1999056723A3 (en) Hemoglobine-haptoglobin complexes for targeted drug delivery
WO2001060412A3 (en) Modification of biopolymers for improved drug delivery
IL161670A0 (en) Thymosin alpha 1 peptide/polymer conjugates
PT1305057E (pt) Composicao de biomateria microparticular para uso medicinal
AR002727A1 (es) El uso de ridogrel para la fabricacion de un medicamento util para el tratamiento de enfermedades digestivas inflamatorias, una composicionfarmaceutica que comprende ridogrel y un procedimiento para preparar dicha composicion.
ATE256134T1 (de) Sulfatierte phosphatidylinositole, ihre herstellung und verwendung
ATE194498T1 (de) Wasserfreies mittel auf lactulosebasis
IL117564A (en) Pharmaceutical and diagnostic compositions containing lysine derivatives
Squibb INTROS
ITMI960133A1 (it) Formulazioni farmaceutiche gastroresistenti contenenti colostro e uso del colostro per il trattamento di disfunzioni erettili
JPH05221862A (ja) 坐剤用医薬組成物
RU2002100065A (ru) Применение верапамила и производных верапамила для получения лекарственных средств с действием, ингибирующим β-глюкуронидазу в ткани человека
CA2326720A1 (en) Hemoglobin-haptoglobin complexes

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 1007561

Country of ref document: ES